Summary of COVID-19 avdoralimab studies

1. Carvelli et al., Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])

207 patient avdoralimab late treatment RCT: 68% higher mortality (p=0.13).
RCT 207 hospitalized COVID-19 patients showing no significant benefit with avdoralimab, a C5a receptor (C5aR1) inhibitor, compared to placebo across three cohorts of patients with varying COVID-19 severity.
Oct 2022, Critical Care Medicine, https://journals.lww.com/10.1097/CCM.0000000000005683, https://c19p.org/carvelli